Methionine sulfoxide reductase A and oxidized CaMKII in structural heart disease
This competitive renewal application is designed to test three new hypotheses about the role of excessive oxidative stress and calmodulin kinase II (CaMKII) in pathological responses to myocardial infarction (MI) and aldosterone (Aldo). These studies will use new genetic mouse models developed by us where the activity of mitochondrial CaMKII, oxidized CaMKII (ox-CaMKII) and methionine sulfoxide reductase A (MsrA), the enzyme that reduces and inactivates ox-CaMKII, are controlled. Each of the inter-related, but independent aims is backed by strong preliminary data.
NIH/NHLBI (HL) - 1R01 HL079031 - 12/1/10-11/30/15
Cardiac-targeted Calmodulin Kinase II Inhibition
This is a proposal to study the consequences of subcellularly-targeted calmodulin kinase inhibition on molecular, cellular and in vivo mechanisms of disease-resistance.
NIH/NHLBI (HL) - 1R01 HL070250 - 03/1/08-2/28/13
CaMKII in Sinus Node Physiology and Disease
The role of CaMKII in cardiac pacemaking by 1) determining its effects on βAR-mediated ‘fight or flight’ sinoatrial (SAN) responses, death, and dysfunction, 2) quantifying CaMKII effects on phospholamban and ryanodine receptors, 3) the effects of NCX1 knock-down and overexpression of SAN automaticity in vitro and in vivo.
NIH/NHLBI (HL) - 1R01 HLHL096652 - 04/1/09–3/31/13
Oxidized CaMKII in atrial fibrillation
The goal of this project is to test the concept that CaMKII is a molecular mechanism for transducing increased oxidative stress with atrial fibrillation in a mouse model.
NIH/NHLBI (HL) - 1R01 HL113001- 04/01/12-03/31/17
Alliance for CaMKII signaling [view website]
This is an international network to test the role of of CaMKII in heart failure and arrhythmias.
Fondation Leducq Transatlantic Network - 10/01/08-09/30/13
T-tubule remodeling and Ca2+-dependent arrhythmogenesis in cardiomyopathies
The main goal is to understand the role of Ca2+-induced Ca2+ release in arrhythmias and heart failure.
Role: Co-investigator (Song, PI) (Anderson 5%)
R01 HL-090905-01 - 12/01/12-11/30/17
Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
US Patent No 6,518,245; Patent Cooperation Treaty #: PCT/US98/01829
Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US Patent No 7,320,959
Calmodulin Kinase II Signaling in Asthma
This is a study of the role of CaMKII in airway smooth muscle.
Sandler Program for Asthma Research - 07/01/08-06/30/11
Dysfunction in ankyrin-based pathways and human arrhythmia
This project will evaluate myocardiocyte models of human diseases caused by ankyrin mutations.
NIH NHLBI - 1R01 HL083422-01 - 12/01/05-11/30/10
Cardiovascular Mechanisms: Training in Investigation
NHLBI - 5 T32 HL07411 (Vaughan, PI, Anderson, Co-PI) - 04/01/05-03/31/10
Baxter Protocol #24779 (Anderson, PI)
AHA Established Investigator
0240072N0873 (Anderson) - $68,182 - 01/01/02 – 12/31/05
Cardiac Arrhythmias Research and Education Foundation, Inc. - 06/01/97-05/31/99
American Heart Association, Southeast Affiliate - 07/01/99- 06/30/01
1K08 HL03727 Mentored Clinical Scientist Award - 07/01/97-06/30/02
NHLBI - AHA Fellowship for Dr.Michelle Khoo (Anderson) - 07/01/01-06/30/03
2P01 HL46681-11 (Roden) (Anderson/Proj 2, Core A) - 08/01/02-7/31/07
Biology of arrhythmia susceptibility
0415229B (Thiel, Anderson sponsor) - 07/01/04-6/30/07
0415157B (Grueter, Anderson co-sponsor) - 07/01/04-6/30/06
Calmodulin Kinase II and Early Afterdepolarizations
5R01 HL62494-05 (PI - Anderson) - 04/01/99-3/31/09